Abstract
Pancreatic neuroendocrine neoplasms (pNEN) comprise less than 5% of all pancreatic neoplasms. Despite their rarity, the incidence has steadily increased in both the USA and Europe over recent decades1,2. In Europe, their age-standardized incidence reached 1 per 100 000 inhabitants in 2018 and an average annual increase of 110.6% was observed2. pNEN represent a heterogeneous group of tumours, including functioning tumours secreting hormones that lead to distinct clinical syndromes, as well as non-functioning tumours with an inherent malignancy risk. pNEN are stratified into pancreatic neuroendocrine tumours (pNET) (grade 1 (G1), grade 2 (G2), and grade 3 (G3)) and pancreatic neuroendocrine carcinoma (pNEC) according to the WHO classification system3,4. The WHO 2017 classification further subdivided G3 tumours into pNET (G3) and pNEC because of genetic, clinical, histological, and prognostic differences that affect subsequent treatment3,5.

This publication has 27 references indexed in Scilit: